CRST – Clinical trials with over 25 years of experience
Scientific publications
Laaksonen N, Bengtström M, Axelin A, Blomster J, Scheinin M, Huupponen R. Success and failure factors of patient recruitment for industry-sponsored clinical trials and the role of the electronic health records-a qualitative interview study in the Nordic countries. Trials. 2022;23:385. doi: 10.1186/s13063-022-06144-9.
Malaspina S, Taimen P, Kallajoki M, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography imaging of prostate cancer: a Phase 1 Proof-of-Concept study. Cancer Biother Radiopharm. 2022;37:205-213. doi: 10.1089/cbr.2021.0322.
Scheinin M, Lovró Z, Maadik IH, Suopanki-Lalowski J, Seyedagha SH, Azhdarzadeh M. A randomized pharmacokinetic-pharmacodynamic evaluation of the potential biosimilar interferon beta-1a product, CinnoVex®. Expert Opin Biol Ther. 2022;22:169-178. doi: 10.1080/14712598.2021.1895745.
Laaksonen N, Bengtström M, Axelin A, Blomster J, Scheinin M, Huupponen R. Clinical trial site identification practices and the use of electronic health records in feasibility evaluations: An interview study in the Nordic countries. Clin Trials. 2021;18:724-731. doi: 10.1177/17407745211038512.
Mäkelä SM, Forssten SD, Kailajärvi M, Langén VL, Scheinin M, Tiihonen K, Ouwehand AC. Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a nonsteroidal anti-inflammatory drug: A randomized, placebo-controlled, double-blind clinical trial. Br J Clin Pharmacol. 2021;87:4625-4635. doi: 10.1111/bcp.14880.
Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:3723-3731. doi: 10.1007/s00259-021-05346-8.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. N Engl J Med. 2021;385:35-45. doi: 10.1056/NEJMoa2032441.
Scheinin M, Junnila J, Reiner G, MacDonald A, Muntau AC. Nitrogen balance after the administration of a prolonged-release protein substitute for phenylketonuria as a single dose in healthy volunteers. Nutrients. 2021;13:3189. doi: 10.3390/nu13093189.
Tolvanen T, Kalliokoski K, Malaspina S, Kuisma A, Lahdenpohja S, Postema EJ, Miller MP, Scheinin M. Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers. J Nucl Med. 2021;62:679-684. doi: 10.2967/jnumed.120.252114.
Vainio PJ, Hietasalo P, Koivisto AL, Kääriäinen S, Turunen J, Virtala M, Vuorinen J, Scheinin M. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22:44. doi: 10.1186/s13063-020-04989-6.
Shahid M, Rinne JO, Scheinin M, Virta J, Marjamäki P, Solin O, Arponen E, Sallinen J, Kuokkanen K, Rouru J: Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the α2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. EJNMMI Res 2020;10:152 https://doi.org/10.1186/s13550-020-00741-y
Scheinin M, Barassi A, Junnila J, Lovró Z, Reiner G, Sarkkinen E, MacDonald A. Amino acid plasma profiles from a prolonged-release protein substitute for phenylketonuria: A randomized, single-dose, four-way crossover trial in healthy volunteers. Nutrients. 2020;12:1653. doi: 10.3390/nu12061653.
Laaksonen N, Varjonen JM, Blomster M, Palomäki A, Vasankari T, Airaksinen J, Huupponen R, Scheinin M, Blomster J. Assessing an Electronic Health Record research platform for identification of clinical trial participants. Contemp Clin Trials Commun. 2020;21:100692. doi: 10.1016/j.conctc.2020.100692.
Dahl T, Chen LB, Scheinin M, Suopanki-Lalowski J, Valge M, Puhakka A, Mikola H, Lovró Z, Meierjohann A, Vuorilehto L, Roth T. Pharmacodynamic and pharmacokinetic profile of SM-1, a triple-drug combination to increase total sleep time. Hum Psychopharmacol. 2019;34:e2716. doi: 10.1002/hup.2716.
Lähdeaho ML, Scheinin M, Vuotikka P, Taavela J, Popp A, Laukkarinen J, Koffert J, Koivurova OP, Pesu M, Kivelä L, Lovró Z, Keisala J, Isola J, Parnes JR, Leon F, Mäki M. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol. 2019;4:948-959. doi: 10.1016/S2468-1253(19)30264-X.
Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M. Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. Neuropsychopharmacology. 2019;44:1667-1673. doi: 10.1038/s41386-019-0368-x.